The Drug-Induced Cardiotoxicity Website and App

XXIV.w

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

Radiation recall pneumonitis

Last update 11/09/2026

(Fr: PnP de rappel en territoire préalablement irradié). Radiation recall pneumonitis is when pulmonary opacities develop exactly in the previously-irradiated area of the chest and lung, following the administration of adriamycin, carmustine, doxorubicin, etoposide, gefitinib, gemcitabine, paclitaxel or trastuzumab. Radiation recall on the skin and esophagus can also occur (PMID 24965480)

Causative drugs

4

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b
III.a
VI.a
VIII.a
X.a
XI.a
XI.i
XIV.a
XIV.f
XIV.l
XIV.o
XVI.e
XXI.c
XXIV.h
XXIV.k
XXIV.m
XXIV.n
XXIV.p
XXIV.s
XXIV.t
XXIV.ad
XXVI.a
XXVIII.a
XXVIII.m
XXX.i
XXXIII.m
XXXIII.y
XXXIV.e
XXXIV.f
XXXIV.g
XXXVI.c
XXXVI.q
XXXVIII.k
XXXVIII.n
XXXVIII.y
II.l
V.a
V.b
V.f
V.h
VI.c
XI.j
XII.a
XII.e
XIII.a
XV.a
XVI.h
XX.c
XX.d
XXIV.j
XXIV.aa
XXIX.h
XXX.p
XXX.s
XXXVI.b
XXXVI.f
XXXVI.h
XXXVI.i
XXXVI.j
XXXVI.n
XXXVI.x
XXXVI.z
XXXVI.ae
XXXVIII.c
XXXVIII.q
I.a
I.c
I.d
II.a
II.m
IV.a
V.e
VII.a
XII.b
XIV.i
XXI.a
XXIV.a
XXIV.b
XXIV.c
XXIV.e
XXIV.r
XXIV.ac
XXIV.ae
XXIX.a
XXIX.i
XXX.h
XXXIII.f
XXXVI.v